SCHEMBL3730655

SCHEMBL3730655

CCCCCS(=O)(=O)CC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.47
CES2 O00748 5/20 0.47
CES1 P23141 5/20 0.47
FAAH O00519 3/20 0.46
NAAA Q02083 1/20 0.45
HSD11B1 P28845 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28538201 0.95 RECQL (0.49) RECQLCES2CES1NAAAHSD11B1
SCHEMBL8761020 0.82 RECQL (0.56) RECQLCES2CES1HSD11B1L3MBTL1
SCHEMBL1516246 0.80 MAPK1 (0.58) RECQLCES1HSD11B1L3MBTL1MAPT
SCHEMBL14079438 0.79 HSD11B1 (0.49) RECQLCES1HSD11B1L3MBTL1MAPT
SCHEMBL9772329 0.77 TSHR (0.46) RECQLHSD11B1L3MBTL1TDP1LMNA
SCHEMBL18903261 0.77 CES1 (0.45) RECQLCES2CES1NAAAHSD11B1
SCHEMBL27948844 0.77 L3MBTL1 (0.56) CES2CES1HSD11B1L3MBTL1MAPT
SCHEMBL9645780 0.77 CES2 (0.41) CES2CES1NAAATDP1
SCHEMBL2188285 0.76 MAPT (0.54) RECQLCES1HSD11B1L3MBTL1MAPT
SCHEMBL3382395 0.75 SMN1; SMN2 (0.57) L3MBTL1MAPTTDP1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1223923-B1 UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS UNIV TEMPLE (US) 2010-03-31 EP disclosed
US-7595347-B2 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents Temple University—Of the Commonwealth System of Higher Education (US) 2009-09-29 US disclosed
EP-1370253-B8 USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY UNIV TEMPLE (US) 2008-11-26 EP disclosed
EP-1370253-B1 USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY UNIV TEMPLE (US) 2008-09-03 EP disclosed
EP-1223923-A4 METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS UNIV TEMPLE (US) 2007-09-05 EP disclosed
EP-1370253-A4 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES UNIV TEMPLE (US) 2005-08-17 EP disclosed
EP-1027330-B1 STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2004-12-08 EP disclosed
US-20040214903-A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents COSENZA STEPHEN C (US) 2004-10-28 US disclosed
CN-1163480-C Styryl sulfone anticancer agents ̹�ն���ѧ 2004-08-25 CN disclosed
US-6767926-B1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2004-07-27 US disclosed
WO-2000059494-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-12 WO disclosed
EP-1027330-A1 STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2000-08-16 EP disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 WO disclosed
US-5800966-A Positive photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-09-01 US disclosed
EP-0569707-B1 Cyclic carbonate compounds, method for producing the same and positive photoresist composition using the same SUMITOMO CHEMICAL CO (JP) 1996-08-14 EP disclosed
EP-0564997-B1 Positive photoresist composition SUMITOMO CHEMICAL CO (JP) 1996-07-17 EP disclosed
US-5420331-A DISSOLUTION INHIBITORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-05-30 US disclosed
US-5397679-A Composition with alkali soluble resin and photoinduced acid precursor SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-03-14 US disclosed
EP-0569707-A2 Cyclic carbonate compounds, method for producing the same and positive photoresist composition using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-11-18 EP disclosed
EP-0564997-A2 Positive photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214903-A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents TOP1, TOP2A, PCNA RECQL 308/4885CES2 345/4885CES1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.